• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉沙病毒糖蛋白的结构保守性及其被中和抗体识别。

Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.

机构信息

Department of Integrative, Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Department of Immunology and Microbiology, Scripps Research, La Jolla, CA 92037, USA; Center for Viral Systems Biology, Scripps Research, La Jolla, CA 92037, USA.

出版信息

Cell Rep. 2023 May 30;42(5):112524. doi: 10.1016/j.celrep.2023.112524. Epub 2023 May 18.

DOI:10.1016/j.celrep.2023.112524
PMID:37209096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10242449/
Abstract

Lassa fever is an acute hemorrhagic fever caused by the zoonotic Lassa virus (LASV). The LASV glycoprotein complex (GPC) mediates viral entry and is the sole target for neutralizing antibodies. Immunogen design is complicated by the metastable nature of recombinant GPCs and the antigenic differences among phylogenetically distinct LASV lineages. Despite the sequence diversity of the GPC, structures of most lineages are lacking. We present the development and characterization of prefusion-stabilized, trimeric GPCs of LASV lineages II, V, and VII, revealing structural conservation despite sequence diversity. High-resolution structures and biophysical characterization of the GPC in complex with GP1-A-specific antibodies suggest their neutralization mechanisms. Finally, we present the isolation and characterization of a trimer-preferring neutralizing antibody belonging to the GPC-B competition group with an epitope that spans adjacent protomers and includes the fusion peptide. Our work provides molecular detail information on LASV antigenic diversity and will guide efforts to design pan-LASV vaccines.

摘要

拉沙热是一种由人畜共患的拉沙病毒(LASV)引起的急性出血热。LASV 糖蛋白复合物(GPC)介导病毒进入,是唯一针对中和抗体的靶标。免疫原设计受到重组 GPC 的亚稳态性质和系统发育上不同 LASV 谱系之间的抗原差异的影响。尽管 GPC 存在序列多样性,但大多数谱系的结构仍不清楚。我们介绍了 LASV 谱系 II、V 和 VII 的预融合稳定三聚体 GPC 的开发和表征,尽管存在序列多样性,但仍显示出结构保守性。与 GP1-A 特异性抗体结合的 GPC 的高分辨率结构和生物物理特性表明了它们的中和机制。最后,我们介绍了一种属于 GPC-B 竞争组的三聚体偏好中和抗体的分离和表征,该抗体的表位跨越相邻的原聚体,并包含融合肽。我们的工作提供了关于 LASV 抗原多样性的分子细节信息,并将指导设计泛 LASV 疫苗的努力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/7cfbd3a553bd/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/7bf5f2b89c66/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/f3c3005b3b7d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/3ed81fc4d11d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/0b2c4f6ff3ac/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/724cec31bc01/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/58a8d3f082b3/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/7cfbd3a553bd/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/7bf5f2b89c66/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/f3c3005b3b7d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/3ed81fc4d11d/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/0b2c4f6ff3ac/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/724cec31bc01/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/58a8d3f082b3/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52c0/10242449/7cfbd3a553bd/gr6.jpg

相似文献

1
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.拉沙病毒糖蛋白的结构保守性及其被中和抗体识别。
Cell Rep. 2023 May 30;42(5):112524. doi: 10.1016/j.celrep.2023.112524. Epub 2023 May 18.
2
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.阐明抗拉沙病毒 GPC-A 中和抗体的作用机制。
Cell Rep. 2022 May 24;39(8):110841. doi: 10.1016/j.celrep.2022.110841.
3
Neutralizing Antibodies against Lassa Virus Lineage I.抗拉萨病毒 I 系的中和抗体。
mBio. 2022 Aug 30;13(4):e0127822. doi: 10.1128/mbio.01278-22. Epub 2022 Jun 22.
4
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.汇聚结构阐明了种系抗体结合和泛拉沙病毒中和的特征。
Cell. 2019 Aug 8;178(4):1004-1015.e14. doi: 10.1016/j.cell.2019.07.020.
5
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability.裂解中期拉沙病毒三聚体引发中和反应,鉴定中和纳米抗体,并揭示位于病毒顶端的弱点位置。
Nat Commun. 2024 Jan 4;15(1):285. doi: 10.1038/s41467-023-44534-y.
6
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.基于病毒糖蛋白基因密码子去优化的拉沙热减毒活疫苗。
mBio. 2020 Feb 25;11(1):e00039-20. doi: 10.1128/mBio.00039-20.
7
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.大多数中和性人源单克隆抗体针对需要拉沙病毒糖蛋白亚单位两者的新型表位。
Nat Commun. 2016 May 10;7:11544. doi: 10.1038/ncomms11544.
8
An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.一种基于信使核糖核酸-脂质纳米颗粒的拉沙病毒疫苗可在小鼠体内诱导产生保护性免疫。
J Virol. 2024 Jun 13;98(6):e0057824. doi: 10.1128/jvi.00578-24. Epub 2024 May 20.
9
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.一种具有复制能力的基于水疱性口炎病毒的拉沙病毒候选疫苗的临床前开发已推进到人体临床试验阶段。
EBioMedicine. 2025 Apr;114:105647. doi: 10.1016/j.ebiom.2025.105647. Epub 2025 Mar 28.
10
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.展示所有主要免疫决定簇的拉沙病毒样颗粒,可用作拉沙热出血热的候选疫苗。
Virol J. 2010 Oct 20;7:279. doi: 10.1186/1743-422X-7-279.

引用本文的文献

1
Molecular organization of the New World arenavirus spike glycoprotein complex.新大陆沙粒病毒刺突糖蛋白复合体的分子结构
Nat Microbiol. 2025 Aug 8. doi: 10.1038/s41564-025-02085-6.
2
Metal-induced conformational changes in the Sabiá virus spike complex.金属诱导的萨比亚病毒刺突复合体构象变化。
Nat Microbiol. 2025 Aug 1. doi: 10.1038/s41564-025-02075-8.
3
Infusion of neutralization into Lassa vaccine design.将中和作用融入拉沙病毒疫苗设计中。

本文引用的文献

1
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability.裂解中期拉沙病毒三聚体引发中和反应,鉴定中和纳米抗体,并揭示位于病毒顶端的弱点位置。
Nat Commun. 2024 Jan 4;15(1):285. doi: 10.1038/s41467-023-44534-y.
2
Efficient isolation of rare B cells using next-generation antigen barcoding.利用下一代抗原标记技术高效分离稀有 B 细胞。
Front Cell Infect Microbiol. 2023 Mar 10;12:962945. doi: 10.3389/fcimb.2022.962945. eCollection 2022.
3
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection.
Trends Immunol. 2025 Jul;46(7):512-524. doi: 10.1016/j.it.2025.05.006. Epub 2025 Jun 24.
4
Mapping the antibody response to Lassa virus vaccination of non-human primates.绘制非人灵长类动物对拉沙病毒疫苗接种的抗体反应图谱。
EBioMedicine. 2025 Apr;114:105673. doi: 10.1016/j.ebiom.2025.105673. Epub 2025 Mar 31.
5
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.一种具有复制能力的基于水疱性口炎病毒的拉沙病毒候选疫苗的临床前开发已推进到人体临床试验阶段。
EBioMedicine. 2025 Apr;114:105647. doi: 10.1016/j.ebiom.2025.105647. Epub 2025 Mar 28.
6
Lassa virus protein-protein interactions as mediators of Lassa fever pathogenesis.拉沙病毒蛋白-蛋白相互作用作为拉沙热发病机制的介质
Virol J. 2025 Feb 28;22(1):52. doi: 10.1186/s12985-025-02669-y.
7
Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV.前融合糖蛋白三聚体的结构导向设计诱导针对拉沙病毒的中和反应。
NPJ Vaccines. 2025 Feb 22;10(1):37. doi: 10.1038/s41541-025-01090-4.
8
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses.通过对疫苗诱导的多克隆抗体反应的结构分析,定义拉沙病毒中和的瓶颈和机会。
Cell Rep. 2024 Sep 24;43(9):114708. doi: 10.1016/j.celrep.2024.114708. Epub 2024 Sep 6.
9
Deep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex.深度突变扫描揭示了拉沙病毒糖蛋白复合物的功能限制和抗体逃逸潜力。
Immunity. 2024 Sep 10;57(9):2061-2076.e11. doi: 10.1016/j.immuni.2024.06.013. Epub 2024 Jul 15.
10
The Adaptive Immune Response against .针对 的适应性免疫反应。
Viruses. 2024 Mar 21;16(3):483. doi: 10.3390/v16030483.
拉沙病毒糖蛋白纳米颗粒可引起中和抗体反应和保护作用。
Cell Host Microbe. 2022 Dec 14;30(12):1759-1772.e12. doi: 10.1016/j.chom.2022.10.018. Epub 2022 Nov 17.
4
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.一种保护性抗体鸡尾酒能够破坏拉沙病毒密集的糖基化外壳。
Sci Transl Med. 2022 Oct 26;14(668):eabq0991. doi: 10.1126/scitranslmed.abq0991.
5
Human LAMP1 accelerates Lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane.人源 LAMP1 可加速拉沙病毒融合,并在强制病毒与非内体膜融合时强力促进融合孔扩张。
PLoS Pathog. 2022 Aug 15;18(8):e1010625. doi: 10.1371/journal.ppat.1010625. eCollection 2022 Aug.
6
Cell surface glycan engineering reveals that matriglycan alone can recapitulate dystroglycan binding and function.细胞表面糖基工程表明,仅仅基质糖蛋白聚糖就可以再现连接蛋白聚糖的结合和功能。
Nat Commun. 2022 Jun 24;13(1):3617. doi: 10.1038/s41467-022-31205-7.
7
Neutralizing Antibodies against Lassa Virus Lineage I.抗拉萨病毒 I 系的中和抗体。
mBio. 2022 Aug 30;13(4):e0127822. doi: 10.1128/mbio.01278-22. Epub 2022 Jun 22.
8
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.阐明抗拉沙病毒 GPC-A 中和抗体的作用机制。
Cell Rep. 2022 May 24;39(8):110841. doi: 10.1016/j.celrep.2022.110841.
9
Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study.从尼日利亚急性拉沙热中康复后的病毒持续存在:前瞻性纵向队列研究的 2 年中期分析。
Lancet Microbe. 2022 Jan;3(1):e32-e40. doi: 10.1016/S2666-5247(21)00178-6. Epub 2021 Nov 8.
10
Climate change increases cross-species viral transmission risk.气候变化增加了跨物种病毒传播的风险。
Nature. 2022 Jul;607(7919):555-562. doi: 10.1038/s41586-022-04788-w. Epub 2022 Apr 28.